Name | (3S)-4-[1-[3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)propanoyl]piperidin-4-yl]-3-[(3S)-1,2,3,4-tetrahydroquinolin-3-yl]butanoic acid |
---|---|
Synonyms | unii-9dlk169hj7 |
Description | JNJ-26076713 is a potent and orally active alpha V integrin antagonist with IC50 values of 2.3 nM and 6.3 nM for alpha(V)beta(3) and alpha(V)beta(5), respectively. JNJ-26076713 inhibits retinal neovascularization[1]. |
---|---|
Related Catalog | |
Target |
αvβ3:2.3 nM (IC50) αvβ5:6.3 nM (IC50) |
In Vitro | JNJ-26076713 (5-5000 nM) 以剂量依赖的方式抑制 FGF2 诱导的 HUVEC 迁移[1]。 JNJ-26076713 (0.1, 1, 和 10 μg) 以剂量依赖的方式抑制鸡胚绒毛尿囊膜 (CAM) 模型的血管生成[1]. |
In Vivo | JNJ-26076713 (30-120 mg/kg; i.g.; 每天两次, 连续5天; 氧诱导视网膜病变 (OIR) 模型C57BL/6J 小鼠) 以剂量依赖的方式抑制视网膜新生血管[1]。 JNJ-26076713 (60 mg/kg; i.g.; 每天两次, 连续5天; 糖尿病 Long-Evans 大鼠) 抑制与糖尿病相关的视网膜血管通透性和白细胞瘀血的增加[1]。 Animal Model: C57BL/6J mice with oxygen-induced retinopathy (OIR) model[1] Dosage: 30, 60, and 120 mg/kg Administration: Oral gavage, twice daily for 5 days Result: Inhibited retinal neovascularization with 33, 43, and 67% inhibition of neovascularization at 30, 60, and 120 mg/kg, respectively. Animal Model: Diabetic Long-Evans rats[1] Dosage: 60 mg/kg Administration: Oral gavage, twice daily for 5 days Result: Reduced leukocyte adhesion with 48% and inhibited retinal vascular permeability in streptozotocin diabetic rats. |
References |
Molecular Formula | C29H38N4O3 |
---|---|
Molecular Weight | 490.63700 |
Exact Mass | 490.29400 |
PSA | 94.56000 |
LogP | 4.59020 |